213 related articles for article (PubMed ID: 19664622)
1. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J
Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622
[TBL] [Abstract][Full Text] [Related]
2. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
4. No correlation between time-linked plasma and CSF Abeta levels.
Le Bastard N; Aerts L; Leurs J; Blomme W; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Dec; 55(8):820-5. PubMed ID: 19695299
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
[TBL] [Abstract][Full Text] [Related]
6. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
[TBL] [Abstract][Full Text] [Related]
7. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation?
Sancesario GM; Esposito Z; Nuccetelli M; Bernardini S; Sorge R; Martorana A; Federici G; Bernardi G; Sancesario G
Exp Neurol; 2010 Jun; 223(2):371-6. PubMed ID: 19664624
[TBL] [Abstract][Full Text] [Related]
8. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
10. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
11. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
12. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
14. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
[TBL] [Abstract][Full Text] [Related]
15. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
[TBL] [Abstract][Full Text] [Related]
16. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
van Rossum IA; Vos S; Handels R; Visser PJ
J Alzheimers Dis; 2010; 20(3):881-91. PubMed ID: 20413876
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
19. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
